Helios® Sirolimus-eluting Coronary Stent with Biodegradable Polymer Technology

Love from heart, perfection in essence

Helios® Sirolimus-eluting Coronary Stent with Biodegradable Polymer Technology

Helios Sirolimus-eluting Coronary Stent With Biodegradable Polymer Technology

Excellent delivery system
Excellent delivery system
Cobalt-chromium alloy
Cobalt-chromium alloy
Titanium oxide coating
Titanium oxide coating
Sirolimus
Sirolimus
Fully biodegradable PLGA drug-controlled release coating
Fully biodegradable PLGA drug-controlled release coating

Effect time

Effect time

Titanium-oxide coating

  • Rutile structure: a long-term stable presence on the surface of the stent.
  • Hemocompatibility: antithrombotic effect – reduces platelet and fibrinogen adhesion and activation.
  • Tissue compatibility: inhibits inflammatory response, restores endothelial cell structure and function, and reduces metal ion release.
Titanium-oxide coating: 10-30nm.
PLGA: Thickness of lumen side 9-13μm, Thickness of wall side 15-19μm.
Co/Cr STRUT: Thickness 80μm.
Sirolimus: 135μg/cm2.

Good biocompatibility makes perfect vascular endothelialization

Titanium-oxide coated stent animal experiment report

Scanning of electron microscopy

Two weeks after stent implantation, most of the titanium-oxide coated stent was basically covered by endothelium, while a large area of the non-titanium-oxide coated stent was not.

At 12 weeks of stent implantation, the endothelial cells on the titanium-oxide coated stent were elongated with a smooth surface, and regularly arranged along the long axis of the cells. The shape of the endothelial cells on the non-coated stent was oval with a large number of bumps on the surface, indicating that the endothelial cells on the stent with coating matured quickly and completed endothelial coverage and endothelial maturation rapidly.

Non-titanium-oxide coated stent
Non-titanium-oxide coated stent
Tianium-oxide coated stent
Tianium-oxide coated stent
Non-titanium-oxide coated stent
Non-titanium-oxide coated stent
Non-titanium-oxide coated stent

Non-titanium-oxide coated stent

Non-titanium-oxide coated stent
Non-titanium-oxide coated stent
Non-titanium-oxide coated stent

Tianium-oxide coated stent

The HOPE study

  • Randomized controlled, multicenter prospective clinical study.
  • 303 patients enrolled in 11 medical centers in China.
  • First randomized controlled study of coronary stents in China.
  • In terms of safety and efficacy, the Helios stent is not inferior to the control group.
In-stent late loss at 9 months
In-stent late loss at 9 months
n-stent late loss at 9 months
The incidence of the cardiac death in 1080 days
In-stent thrombotic events in 1080 days
In-stent thrombotic events in 1080 days

Technology & Innovation

SPECIFICATION

Diameter Length(mm)
10 13 16 19 22 28 38
2.50 JHLD-2510 JHLD-2513 JHLD-2516 JHLD-2519 JHLD-2522 JHLD-2528 JHLD-2538
2.75 JHLD-2710 JHLD-2713 JHLD-2716 JHLD-2719 JHLD-2722 JHLD-2728 JHLD-2738
3.00 JHLD-3010 JHLD-3013 JHLD-3016 JHLD-3019 JHLD-3022 JHLD-3028 JHLD-3038
3.50 JHLD-3510 JHLD-3513 JHLD-3516 JHLD-3519 JHLD-3522 JHLD-3528 JHLD-3538
4.00 JHLD-4010 JHLD-4013 JHLD-4016 JHLD-4019 JHLD-4022 JHLD-4028 JHLD-4038

Pressure
(ATM, bars)
Balloon Size (mm)
2.50 2.75 3.00 3.50 4.00
2 2.32 2.55 2.78 3.24 3.71
4 2.40 2.64 2.88 3.36 3.84
NP 6 2.50 2.75 3.00 3.50 4.00
8 2.56 2.82 3.07 3.58 4.09
10 2.61 2.87 3.13 3.65 4.17
12 2.65 2.92 3.18 3.71 4.24
14 2.70 2.97 3.24 3.78 4.32
RBP 16 2.75 3.03 3.30 3.85 4.40
18 2.80 3.08 3.36 3.92 4.48